Biomarker for diagnosing working of nervonic acid supplemented for ischemic hypoxic encephalopathy and application of biomarker

A biomarker and nervonic acid technology, applied in disease diagnosis, biological testing, biomaterial analysis, etc., can solve problems such as few researches

Active Publication Date: 2021-10-12
BAO FENG BIOTECH (BEIJING) CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there are no clear studi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for diagnosing working of nervonic acid supplemented for ischemic hypoxic encephalopathy and application of biomarker
  • Biomarker for diagnosing working of nervonic acid supplemented for ischemic hypoxic encephalopathy and application of biomarker
  • Biomarker for diagnosing working of nervonic acid supplemented for ischemic hypoxic encephalopathy and application of biomarker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] 1. Construction of ischemic-hypoxic encephalopathy model

[0031] Thirty-two 7-day-old SD neonatal rats (purchased from Liaoning Changsheng Biotechnology Co., Ltd.) were anesthetized by inhalation of isoflurane, and placed in a supine position. The skin of the neck was cut open, the tissue was separated, the left common carotid artery was ligated, and the incision was sutured , after the operation, the pups returned to the mother mice and observed for 2 hours, then put them into a sealed box, inhaled the mixed gas of 92% nitrogen + 8% oxygen for 2 hours, 3 died, and 29 survived. Hypoxic-ischemic encephalopathy rat model (HIE model rat).

[0032] 2. Sample collection

[0033] Twenty-nine HIE model mice were randomly divided into 2 groups, 16 rats were fed with Yuanbao Feng nerve acid oil group (NA group) and 13 rats were fed with placebo group (CK group). According to the dosage conversion method between humans and rats, the dosage was calculated and determined. The Yu...

Embodiment 2

[0060] External data, logistic regression model validation

[0061] External data: model verification sample group of 16 (external data, newborn 7-day-old SD rats were purchased from Liaoning Changsheng Biotechnology Co., Ltd., constructed according to the model of ischemic hypoxic encephalopathy in Example 1) for logistic regression model For verification, the model was built according to the method in Example 1, and randomly divided into two groups, feeding 8 rats in the Yuanbao maple nervous acid oil group (NA group) and placebo group (CK group) respectively, feeding for 30 days, and collecting blood. Serum was collected.

[0062] According to the method in Example 1, F6: phosphoceramide (d18:1 / 24:1 (15Z)), F1: sphingomyelin (d18:1 / 15:0), F2: docosapentaenoic acid , F3: hexanoylcarnitine, F4: phosphatidylcholine (22:6 ( / 20:5), F5: the content of 2-hydroxyhexadecanoylcarnitine, to verify the accuracy of the model results in Example 1, And draw the corresponding ROC curve, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a biomarker for diagnosing the working of nervonic acid supplemented for ischemic hypoxic encephalopathy and application of the biomarker. The biomarker comprises ceramide phosphate (d18: 1/24: 1(15Z)), and the ceramide phosphate is combined with any one selected from sphingomyelin (d18: 1/15: 0), docosapentaenoic acid, hexanoyl carnitine, phosphatidylcholine (22: 6(/20: 5) or 2-hydroxyhexadecanoylcarnitine to diagnose whether the nervonic acid supplemented for the ischemic-hypoxic encephalopathy takes effect or not. According to the biomarker for diagnosing the working of nervonic acid supplemented for ischemic hypoxic encephalopathy, by detecting the biomarker, whether nervonic acid is absorbed and transformed by a body suffering from the ischemic hypoxic encephalopathy or not can be judged, and guiding significance is provided for judging whether acer truncatum bunge nervonic acid oil or similar products have effects or not when the acer truncatum bunge nervonic acid oil or similar products are taken by patients with the ischemic hypoxic encephalopathy.

Description

technical field [0001] The invention belongs to the technical field of biological detection, and in particular relates to a biomarker for diagnosing the effect of nervous acid supplementation on hypoxic-ischemic encephalopathy and its application. Background technique [0002] Hypoxic-ischemic encephalopathy refers to diffuse brain tissue damage caused by acute cerebral hypoxia leading to oxygen supply and utilization that cannot meet the metabolic needs of brain tissue, and is more common in newborns. Neonatal hypoxic-ischemic encephalopathy (hypoxie-ischemic encephalopathy, HIE) is an important clinical factor leading to neonatal mortality and neurodevelopmental disorders. Relevant data point out that the incidence of hypoxic ischemic encephalopathy in newborns is as high as 8%. If timely treatment measures are not taken, it will inevitably lead to different degrees of cognitive impairment and behavioral impairment in children. Analysis of the etiology and pathology of th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/92
CPCG01N33/92G01N2800/7038G01N2800/7019G01N2800/52G01N2800/2871
Inventor 陈显扬宋王婷张珂韩佳睿薛腾
Owner BAO FENG BIOTECH (BEIJING) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap